As of 2025-06-22, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -5.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 1,014.63 mil USD. OCUL's TTM EBITDA according to its financial statements is -200.30 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 9.8x | 7.9x |
| Forward P/E multiples | 10.7x - 17.1x | 14.2x |
| Fair Price | (11.67) - (10.59) | (12.13) |
| Upside | -243.5% - -230.2% | -249.2% |
| Date | EV/EBITDA |
| 2025-06-18 | -5.22 |
| 2025-06-17 | -5.20 |
| 2025-06-16 | -5.56 |
| 2025-06-13 | -5.54 |
| 2025-06-12 | -5.72 |
| 2025-06-11 | -5.61 |
| 2025-06-10 | -5.69 |
| 2025-06-09 | -5.68 |
| 2025-06-06 | -5.77 |
| 2025-06-05 | -5.33 |
| 2025-06-04 | -5.26 |
| 2025-06-03 | -5.22 |
| 2025-06-02 | -5.05 |
| 2025-05-30 | -4.97 |
| 2025-05-29 | -5.07 |
| 2025-05-28 | -4.87 |
| 2025-05-27 | -4.12 |
| 2025-05-23 | -4.41 |
| 2025-05-22 | -4.34 |
| 2025-05-21 | -4.41 |
| 2025-05-20 | -4.64 |
| 2025-05-19 | -4.57 |
| 2025-05-16 | -4.34 |
| 2025-05-15 | -4.30 |
| 2025-05-14 | -4.11 |
| 2025-05-13 | -4.17 |
| 2025-05-12 | -4.48 |
| 2025-05-09 | -4.21 |
| 2025-05-08 | -4.52 |
| 2025-05-07 | -4.21 |
| 2025-05-06 | -4.31 |
| 2025-05-05 | -4.75 |
| 2025-05-02 | -5.60 |
| 2025-05-01 | -5.38 |
| 2025-04-30 | -5.20 |
| 2025-04-29 | -5.13 |
| 2025-04-28 | -5.07 |
| 2025-04-25 | -4.73 |
| 2025-04-24 | -4.88 |
| 2025-04-23 | -4.84 |
| 2025-04-22 | -4.89 |
| 2025-04-21 | -4.65 |
| 2025-04-17 | -4.41 |
| 2025-04-16 | -4.30 |
| 2025-04-15 | -4.59 |
| 2025-04-14 | -4.62 |
| 2025-04-11 | -4.25 |
| 2025-04-10 | -3.69 |
| 2025-04-09 | -4.04 |
| 2025-04-08 | -3.39 |